A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury

Kuba, Keiji, Imai, Yumiko, Rao, Shuan, Gao, Hong, Guo, Feng, Guan, Bin, Huan, Yi, Yang, Peng +16 more·2005·Nature Medicine
DOI 10.1038/nm1267

Cited by (1,008)

Items 901–1,000 of 1,008

  1. Prevention of SARS-CoV-2 cell entry: insight fromin silicointeraction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2
    Gideon Ampoma Gyebi, Adegbenro Peter Adegunloye, Ibrahim M. Ibrahim, Oludare Michael Ogunyemi, Saheed Olanrewaju Afolabi, Olalekan Bukunmi Ogunro · 2020 · Journal of Biomolecular Structure and Dynamics
  2. Obesity alters Ace2 and Tmprss2 expression in lung, trachea, and esophagus in a sex-dependent manner: Implications for COVID-19
    Dylan C. Sarver, Guang William Wong · 2020 · Biochemical and Biophysical Research Communications
  3. Angiotensin-converting enzyme inhibitor captopril attenuates ventilator-induced lung injury in rats
    Jiunn‐Song Jiang, Leng-Fang Wang, Hsiu‐Chu Chou, Chung‐Ming Chen · 2007 · Journal of Applied Physiology
  4. COVID‐19 and renin‐angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) ‐ Is there any scientific evidence for controversy?
    Aneta Aleksova, Federico Ferro, Giulia Gagno, Chiara Cappelletto, Daniela Santon, Maddalena Rossi, Giuseppe Ippolito, Alimuddin I. Zumla, Antonio Paolo Beltrami, Gianfranco Sinagra · 2020 · Journal of Internal Medicine
  5. Vaccines and Therapies in Development for SARS-CoV-2 Infections
    David Bin-Chia Wu, Raghuram Koganti, Upendra Pradeep Lambe, Tejabhiram Yadavalli, Shyam Sundar Nandi, Deepak Shukla · 2020 · Journal of Clinical Medicine
  6. Association Between Diabetes and COVID-19: A Retrospective Observational Study With a Large Sample of 1,880 Cases in Leishenshan Hospital, Wuhan
    Zeming Liu, Jinpeng Li, Jianglong Huang, Liang Guo, Rongfen Gao, Kuan Luo, Guang Zeng, Tingbao Zhang, Meilin Yi, Yihui Huang et al. · 2020 · Frontiers in Endocrinology
  7. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety
    Saghir Akhtar, Ibrahim F. Benter, Mohammed Ibn-Mas’ud Danjuma, Suhail A.R. Doi, Syed Shahzad Hasan, Abdella M. Habib · 2020 · Journal of drug targeting
  8. Strategies for Targeting SARS CoV-2: Small Molecule Inhibitors—The Current Status
    Narasimha Murthy Beeraka, Surya Prabha Sadhu, SubbaRao V. Madhunapantula, Rajeswara Rao Pragada, Andrey А. Svistunov, Vladimir Nikolaevich Nikolenko, Л.М. Михалева, Gjumrakch M. Aliev · 2020 · Frontiers in Immunology
  9. Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis
    Chao Quan, Caiyan Li, Han Ma, Yisha Li, Huali Zhang · 2020 · Clinical Microbiology Reviews
  10. A molecular dynamics simulation study of the ACE2 receptor with screened natural inhibitors to identify novel drug candidate against COVID-19
    Neha Srivastava, Prekshi Garg, Prachi Srivastava, Prahlad Kishore Seth · 2021 · PeerJ
  11. ACE2 expression in adipose tissue is associated with cardio-metabolic risk factors and cell type composition—implications for COVID-19
    Julia S. El-Sayed Moustafa, Anne Jackson, Sarah M. Brotman, Li Guan, Sergio Villicaña, Amy L. Roberts, Antonino Zito, Lori L. Bonnycastle, Michael R. Erdos, Narisu Narisu et al. · 2022 · International Journal of Obesity
  12. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
    Yaozong Chen, Lulu Sun, Irfan Ullah, Guillaume Beaudoin-Bussières, Sai Priya Anand, Andrew P. Hederman, William David Tolbert, Rebekah T. Sherburn, Dung Ngoc Pham Nguyen, Lorie Marchitto et al. · 2022 · Science Advances
  13. Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: Possible involvement of angiotensin-converting enzyme-2
    Su-Xia Han, Guangming He, Tao Wang, Lei Chen, Yunye Ning, Feng Luo, Jin An, Ting Yang, Jiajia Dong, Zenglin Liao · 2010 · Toxicology and Applied Pharmacology
  14. The COVID-19 Pandemic and its Impact on the Cardio-Oncology Population
    Ishan Asokan, Soniya V. Rabadia, Eric H. Yang · 2020 · Current Oncology Reports
  15. The Yin and Yang of ACE/ACE2 Pathways: The Rationale for the Use of Renin-Angiotensin System Inhibitors in COVID-19 Patients
    Loris Zamai · 2020 · Cells
  16. Pathophysiology of Cardiovascular Complications in COVID-19
    Vladimír Petrovič, Dina Radenković, Goran Radenković, Vukica Djordjevic, Maciej Banach · 2020 · Frontiers in Physiology
  17. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention
    Alessio Danilo Inchingolo, Angelo Michele Inchingolo, Ioana Roxana Bordea, Giuseppina Malcangi, Edit Xhajanka, Antônio Scarano, Felice Lorusso, Marco Farronato, Gianluca Martino Tartaglia, Ciro Gargiulo Isacco et al. · 2021 · Microorganisms
  18. Interaction of SARS-CoV-2 with cardiomyocytes: Insight into the underlying molecular mechanisms of cardiac injury and pharmacotherapy
    Abdi, Abdulhamid, AlOtaiby, Shahad, Badarin, Firas Al, Khraibi, Ali, Hamdan, Hamdan, Nader, Moni · 2022 · Biomedicine & Pharmacotherapy
  19. A Review of COVID-19 in Relation to Metabolic Syndrome: Obesity, Hypertension, Diabetes, and Dyslipidemia
    Elias Makhoul, Joseph L. Aklinski, Jesse Miller, Cara Leonard, Sean Backer, Payal Kahar, Mayur S. Parmar, Deepesh Khanna · 2022 · Cureus
  20. SARS-CoV-2 activates the TLR4/MyD88 pathway in human macrophages: A possible correlation with strong pro-inflammatory responses in severe COVID-19
    Sabina Sahanic, Richard Hilbe, Christina Dünser, Piotr Tymoszuk, Judith Löffler‐Ragg, Dietmar Rieder, Zlatko Trajanoski, Anne Krogsdam, Egon Demetz, Maria Yurchenko et al. · 2023 · Heliyon
  21. Coronavirus Disease 2019 and the Cerebrovascular‐Cardiovascular Systems: What Do We Know So Far?
    Anthony S. Larson, Luis Emilio Savastano, Ramanathan Kadirvel, David F. Kallmes, Ameer E Hassan, Waleed Brinjikji · 2020 · Journal of the American Heart Association
  22. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality
    Lucinda Smart, Neil Fawkes, Paul Goggin, Graham Pennick, Kim Drummond Rainsford, Bruce R. Charlesworth, Neil Shah · 2020 · Inflammopharmacology
  23. COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection
    Stanisław Surma, Maciej Banach, Joanna Lewek · 2021 · Lipids in Health and Disease
  24. Repurposing existing drugs for COVID-19: an endocrinology perspective
    Flavio Cadegiani · 2020 · BMC Endocrine Disorders
  25. How Does SARS-CoV-2 Affect the Central Nervous System? A Working Hypothesis
    Fabio Panariello, Lorenzo Cellini, Maurizio Speciani, Diana De Ronchi, Anna Rita Atti · 2020 · Frontiers in Psychiatry
  26. Angiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapies
    Girish Pathangey, Priyal Fadadu, Alexa R. Hospodar, Amr E. Abbas · 2020 · American Journal of Physiology-Lung Cellular and Molecular Physiology
  27. SARS-CoV-2 Spike Protein Suppresses ACE2 and Type I Interferon Expression in Primary Cells From Macaque Lung Bronchoalveolar Lavage
    Y. Sui, Jianping Li, D. Venzon, J. Berzofsky · 2021 · Frontiers in Immunology
  28. Diabetes increases the risk of COVID-19 in an altitude dependent manner: An analysis of 1,280,806 Mexican patients
    Juan Alonso León-Abarca, Arianna Portmann-Baracco, Mayte Bryce‐Alberti, Carlos Ruiz-Sánchez, Roberto A. Accinelli, Jorge Soliz, Gustavo Francisco Gonzales · 2021 · PLoS ONE
  29. Quantifying Renin-Angiotensin-System Alterations in COVID-19
    Fabrizio Pucci, Filippo Annoni, Robson A.S. Santos, Fabio Silvio Taccone, Marianne J. Rooman · 2021 · Cells
  30. Cationic nanoparticles directly bind angiotensin-converting enzyme 2 and induce acute lung injury in mice
    Yang Sun, Feng Guo, Zhen Zou, Chenggang Li, Xiaoxu Hong, Yan Zhao, Chenxuan Wang, Hongliang Wang, Haolin Liu, Peng Yang et al. · 2015 · Particle and Fibre Toxicology
  31. SARS‐CoV‐2 and the possible connection to ERs, ACE2, and RAGE: Focus on susceptibility factors
    Roberta Sessa Stilhano, Angélica Jardim Costa, Michelle Sayuri Nishino, Shahin Shams, Cynthia Silva Bartolomeo, Ana Cristina Breithaupt‐Faloppa, Eduardo Alexandre Silva, Ana Lopez Ramirez, Carla Máximo Prado, Rodrigo Portes Ureshino · 2020 · The FASEB Journal
  32. Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes Platform to Study SARS-CoV-2 Related Myocardial Injury
    Chun‐Ka Wong, Hayes K. H. Luk, Wing‐Hon Lai, Yee‐Man Lau, Ruiqi Zhang, Antonio C. P. Wong, George Chi-Shing Lo, Kwok‐Hung Chan, Ivan Fan‐Ngai Hung, Hung‐Fat Tse et al. · 2020 · Circulation Journal
  33. Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review
    Morteza Izadi, Luca Cegolon, Mohammad Javanbakht, Ali Sarafzadeh, Hassan Abolghasemi, Gholam Hossein Alishiri, Shi Zhao, Behzad Einollahi, Mandana Kashaki, Nematollah Jonaidi Jafari et al. · 2020 · International Immunopharmacology
  34. Bioactive compounds and probiotics–a ray of hope in COVID-19 management
    Indu Bhushan, Mahima Sharma, Malvika Mehta, Shivi Badyal, Varun Sharma, Indu Sharma, Hemender Singh, Srinivas Sistla · 2021 · Food Science and Human Wellness
  35. SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review
    Jahangir Emrani, Maryam Ahmed, Liesl K. Jeffers-Francis, John C. Teleha, Chishimba Nathan Mowa, Robert Howard Newman, Misty D. Thomas · 2021 · International Journal of Biological Macromolecules
  36. Mechanisms contributing to adverse outcomes of COVID-19 in obesity
    Manu Sudhakar, Winfred Sofi Beaula, Gowri Meiyazhagan, Venkatachalam Deepa Parvathi · 2022 · Molecular and Cellular Biochemistry
  37. Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases
    Xinling Wang, Shuai Xia, Qian Wang, Wei Xu, Weihua Li, Lu Lu, Shibo Jiang · 2020 · International Journal of Molecular Sciences
  38. COVID-19-related organ dysfunction and management strategies on the intensive care unit: a narrative review
    Peter Brendon Sherren, Marlies Ostermann, Sangita Agarwal, Christopher I. S. Meadows, Nicholas Ioannou, Luigi Camporota · 2020 · British Journal of Anaesthesia
  39. Mutations in the phosphorylation sites of SARS-CoV-2 encoded nucleocapsid protein and structure model of sequestration by protein 14-3-3
    H.Y. Lim Tung, Pierre Limtung · 2020 · Biochemical and Biophysical Research Communications
  40. COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity
    Kenneth H. Lundstrom, Altijana Hromić‐Jahjefendić, Esma Bilajac, Alaa A. A. Aljabali, Katarina Baralić, Nagwa A. Sabri, Eslam Mansour Shehata, Mohamed Raslan, Ana Cláudia Barbosa Honório Ferreira, Lidiane Orlandi et al. · 2022 · Cellular Signalling
  41. Human transferrin receptor can mediate SARS-CoV-2 infection
    Zhiyi Liao, Chaoming Wang, Xiaopeng Tang, Mengli Yang, Zilei Duan, Lei Liu, Shuaiyao Lu, Lei Ma, Ruomei Cheng, Wang Gan et al. · 2024 · Proceedings of the National Academy of Sciences
  42. Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications
    Eleanor C. Murray, Maciej Tomaszewski, Tomasz Jan Guzik · 2020 · Cardiovascular Research
  43. COVID-19 : physiopathologie d’une maladie à plusieurs visages
    Vincent Bonny, Alexis Maillard, Cyril Mousseaux, Léo Plaçais, Quentin Richier · 2020 · La Revue de Médecine Interne
  44. Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study
    Reza Nejat, Ahmad Shahir Sadr · 2020 · In Silico Pharmacology
  45. Angiotensin‐(1‐7), the product of ACE2 ameliorates NAFLD by acting through its receptor Mas to regulate hepatic mitochondrial function and glycolipid metabolism
    Li‐Ni Song, Jing‐Yi Liu, Tingting Shi, Yichen Zhang, Xin Zhong, Xi Cao, Jin‐Kui Yang · 2020 · The FASEB Journal
  46. ACE2: from protection of liver disease to propagation of COVID-19
    Fiona J. Warner, Harinda Rajapaksha, Nicholas Adam Shackel, Chandana B. Herath · 2020 · Clinical Science
  47. COVID-19 and Gut Microbiota: A Potential Connection
    Swati Rajput, Deepanshu Paliwal, Manisha Naithani, Ashish Kothari, Kiran Meena, Satyavati V. Rana · 2021 · Indian Journal of Clinical Biochemistry
  48. Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
    Daniela Mokrá, Juraj Mokrý · 2021 · International Journal of Molecular Sciences
  49. SARS-CoV-2 N Protein Induces Acute Lung Injury in Mice via NF-ĸB Activation
    Jie Lai Xia, Wenqi Tang, Jiangmei Wang, Dengming Lai, Qi Xu, Ruoqiong Huang, Yaoqin Hu, Xiaojue Gong, Jiajie Fan, Qiang Shu et al. · 2021 · Frontiers in Immunology
  50. A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection
    Luise Hassler, Jan A Wysocki, Ian Arthur Gelarden, Isha Sharma, Αναστασία Τοματσίδου, Minghao Ye, Haley Gula, Vlad Nicoleascu, Glenn C. Randall, Sergii Pshenychnyi et al. · 2022 · Journal of the American Society of Nephrology
  51. COVID-19 and the Renin-Angiotensin System
    Line P. Malha, Franco B. Mueller, Mark S. Pecker, Samuel J. Mann, Phyllis August, Peter U. Feig · 2020 · Kidney International Reports
  52. COVID-19: Living through Another Pandemic
    Essam Eldin A. Osman, Peter L. Toogood, Nouri Neamati · 2020 · ACS Infectious Diseases
  53. Activation of ang-(1-7)/mas receptor is a possible strategy to treat coronavirus (SARS-CoV-2) infection
    Magalhaes, Giselle Santos, Rodrigues-Machado, Maria da Gloria, Motta-Santos, Daisy, Campagnole-Santos, Maria Jose, Santos, Robson A. Souza · 2020 · Frontiers in Physiology
  54. Clinical characteristics of 194 cases of COVID-19 in Huanggang and Taian, China
    Hong Zhang, Wenli Shang, Qinghua Liu, Xuejing Zhang, Maochuan Zheng, Maokui Yue · 2020 · Infection
  55. The potential role of the carotid body in COVID-19
    Andrea Porzionato, Aron Emmi, Elena Stocco, Silvia Barbon, Rafael Boscolo-berto A, Veronica Macchi, Raffaele De · 2020 · American Journal of Physiology-Lung Cellular and Molecular Physiology
  56. Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment
    Jinwen Luo, Xiao Zhu, Jie Jian, Xu Chen, Kai Yin · 2020 · Acta Biochimica et Biophysica Sinica
  57. Intrarenal Angiotensin-Converting Enzyme: the Old and the New
    Silas Allen Culver, Caixia Li, Helmy M. Siragy · 2017 · Current Hypertension Reports
  58. SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics
    Ruchir Gupta, Jacob G. Charron, Cynthia L. Stenger, Jared Painter, Hunter Steward, Taylor W. Cook, William Faber, Austin Frisch, Eric Lind, Jacob M. Bauss et al. · 2020 · Journal of Biological Chemistry
  59. COVID-19–associated Acute Respiratory Distress Syndrome Clarified: A Vascular Endotype?
    Nilam S. Mangalmurti, John P. Reilly, Douglas B. Cines, Nuala J. Meyer, Christopher A. Hunter, Andrew E. Vaughan · 2020 · American Journal of Respiratory and Critical Care Medicine
  60. Pathogenesis and Management of Myocardial Injury in Coronavirus Disease 2019
    Zhiyao Wei, Yong‐Jian Geng, Ji Huang, Hai‐Yan Qian · 2020 · European Journal of Heart Failure
  61. The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study
    Orianne Villard, David Morquin, Nicolas Molinari, I. Raingeard, Nicolas Nagot, Jean‐Paul Cristol, Boris Jung, C. Roubille, Vincent Foulongne, Pierre Fesler et al. · 2020 · Journal of Clinical Medicine
  62. Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?
    Alejandro Romero, Eva Ramos, Francisco Javier Lopez-Munoz, Emilio Gil‐Martín, Germaine Escames, Russel Joseph Reiter · 2020 · Cellular and Molecular Neurobiology
  63. The Scientific Foundation of Chinese Herbal Medicine against COVID-19
    Elaine Lai‐Han Leung, Hudan Pan, Yu-Feng Huang, Xingxing Fan, Wan-Ying Wang, Fang He, Jun Cai, Hua Zhou, Liang Liu · 2020 · Engineering
  64. Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
    Cristina Cerqueira Vieira, Lucas Nery, Ludimila de Barcelos Ubaldo Martins, Luiz Gustavo Pessoa Pires Jabour, Raphael Figuiredo Dias, Ana Cristina Simões e Silva · 2020 · Current Drug Targets
  65. Clinical characteristics and analysis of risk factors for disease progression of COVID-19: A retrospective Cohort Study
    Zhengtong Lv, Shubin Lv · 2020 · International Journal of Biological Sciences
  66. The Renin–Angiotensin–Aldosterone System and Coronavirus Disease 2019
    Eliécer Coto, Pablo Avanzas y, Juan Gómez · 2021 · European Cardiology Review
  67. Renal Manifestations of Covid-19: Physiology and Pathophysiology
    Zaher Armaly, Safa Kinaneh, Karl L. Skorecki · 2021 · Journal of Clinical Medicine
  68. COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart
    Maurizio Pesce, Piergiuseppe Agostoni, Hans Erik Bøtker, Bianca J.J.M. Brundel, Sean M. Davidson, Raffaele De Caterina, Péter Ferdinandy, Henrique Girão, Mariann Gyöngyösi, Jean‐Sébastien Hulot et al. · 2021 · Cardiovascular Research
  69. Do Changes in ACE-2 Expression Affect SARS-CoV-2 Virulence and Related Complications: A Closer Look into Membrane-Bound and Soluble Forms
    Huseyin Cagatay Yalcin, Vijayakumar Sukumaran, Mahmoud Khatib A. A. Al-Ruweidi, Samar Shurbaji · 2021 · International Journal of Molecular Sciences
  70. ACE2 and TMPRSS2 in human saliva can adsorb to the oral mucosal epithelium
    Fucun Zhu, Yi Zhong, Huan Ji, Ran Ge, Lu Guo, Haiyang Song, Heming Wu, Pengfei Jiao, Sheng Li, Chenxing Wang et al. · 2021 · Journal of Anatomy
  71. Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation
    Anthony J. Turner, Natalia N. Nalivaeva · 2022 · Peptides
  72. Plasma Angiotensin II Is Increased in Critical Coronavirus Disease 2019
    Rafael Ludemann Camargo, Bruna Bombassaro, Milena Monfort‐Pires, Eli Mansour, André C. Palma, Luciana C. Ribeiro, Raisa Gusso Ulaf, Ana Flávia Bernardes, Thyago A. Nunes, Marcus Vinicius Rodrigues de Agrela et al. · 2022 · Frontiers in Cardiovascular Medicine
  73. Spike-mediated ACE2 down-regulation was involved in the pathogenesis of SARS-CoV-2 infection
    Xiang Gao, Shengyuan Zhang, Jizhou Gou, Yanling Wen, Lujie Fan, Jian Zhou, Guangde Zhou, Gang Xu, Zheng Zhang · 2022 · Journal of Infection
  74. A Place in Our Hearts for the Lowly Angiotensin 1-7 Peptide?
    Timothy L. Reudelhuber · 2006 · Hypertension
  75. Smoking, vaping and hospitalization for COVID-19
    Konstantinos E. Farsalinos, Anastasia Barbouni, RAYMOND S. NIAURA · 2020 · Qeios
  76. Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse
    Yiwu Yan, Qiang Liu, Ning Li, Jianchao Du, Xiao Li, Chang Li, Ningyi Jin, Chengyu Jiang · 2015 · Science China Life Sciences
  77. A cytokine super cyclone in COVID-19 patients with risk factors: the therapeutic potential of BCG immunization
    Betcy Susan Johnson, Malini Laloraya · 2020 · Cytokine & Growth Factor Reviews
  78. A Quantitative and Radiomics approach to monitoring ARDS in COVID-19 patients based on chest CT: a retrospective cohort study
    Yahong Chen, Yi Wang, Yuwei Zhang, Na Zhang, Shuang Zhao, Hanjiang Zeng, Wen Deng, Zixing Huang, Sanyuan Liu, Bin Song · 2020 · International Journal of Medical Sciences
  79. Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review
    Annamaria Mascolo, Cristina Scavone, Concetta Rafaniello, Carmen Ferrajolo, Giorgio Racagni, Liberato Berrino, Giuseppe Paolisso, Francesco Rossi, Annalisa Capuano · 2020 · Frontiers in Cardiovascular Medicine
  80. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor
    Murat Öz, Dietrich Ernst Lorke, Nadine Kabbani · 2020 · Pharmacology & Therapeutics
  81. A nanotechnological approach in the current therapy of COVID-19: model drug oseltamivir-phosphate loaded PLGA nanoparticles targeted with spike protein binder peptide of SARS-CoV-2
    Burcu Uçar, Tayfun Acar, Pelin Pelit Arayıcı, Serap Derman · 2021 · Nanotechnology
  82. Potential benefits of ginseng against COVID-19 by targeting inflammasomes
    Young‐Su Yi · 2022 · Journal of Ginseng Research
  83. Dissecting the molecular mechanism of cepharanthine against COVID-19, based on a network pharmacology strategy combined with RNA-sequencing analysis, molecular docking, and molecular dynamics simulation
    Jiaqin Liu, Taoli Sun, Sa Liu, Jian Liu, Senbiao Fang, Shengyu Tan, Yucheng Zeng, Bikui Zhang, Wenqun Li · 2022 · Computers in Biology and Medicine
  84. ACE2 and the Homolog Collectrin in the Modulation of Nitric Oxide and Oxidative Stress in Blood Pressure Homeostasis and Vascular Injury
    Guang Yang, Pei‐Lun Chu, Lars Christian Rump, Thu H. Le, Johannes Stegbauer · 2016 · Antioxidants and Redox Signaling
  85. γδ T Cells Provide Protective Function in Highly Pathogenic Avian H5N1 Influenza A Virus Infection
    Peng Dong, Xiangwu Ju, Yiwu Yan, Siya Zhang, Menghua Cai, Huaishan Wang, Hui Chen, Yu Hu, Lianxian Cui, Jianmin Zhang et al. · 2018 · Frontiers in Immunology
  86. Molecules in pathogenesis: angiotensin converting enzyme 2 (ACE2)
    Owen J Wiese, Annalise E. Zemlin, Tahir S. Pillay · 2020 · Journal of Clinical Pathology
  87. Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
    Gábor Kriszta, Zsófia Kriszta, Szilárd Váncsa, Péter Hegyi, Levente Frim, Bálint Mihály Erőss, Péter Hegyi, Gábor Pethö, Erika Pintér · 2021 · Frontiers in Pharmacology
  88. COVID-19 Vaccine and Hyperosmolar Hyperglycemic State
    Mohammed A Abu-Rumaileh, Ahmad Gharaibeh, Naser Eddin Gharaibeh · 2021 · Cureus
  89. The Altered Anatomical Distribution of ACE2 in the Brain With Alzheimer’s Disease Pathology
    Huan Cui, Si Su, Yan Wei Cao, Chao Ma, Wenying Qiu · 2021 · Frontiers in Cell and Developmental Biology
  90. An ACE2/Mas-related receptor MrgE axis in dopaminergic neuron mitochondria
    Rita Valenzuela, Ana Isabel Rodriguez-Perez, Maria A. Costa-Besada, Rafael Rivas‐Santisteban, Pablo Garrido‐Gil, Andrea López-López, Gemma Navarro, José Luis Lanciego, Rafael Franco, José Luis Labandeira-García · 2021 · Redox Biology
  91. Strong Association of Angiotensin Converting Enzyme-2 Gene Insertion/Deletion Polymorphism with Susceptibility to SARS-CoV-2, Hypertension, Coronary Artery Disease and COVID-19 Disease Mortality
    Rashid Mir, Rashid Mir, Mushabab Ayed Abdullah Alghamdi, Badr Abdulmohsin Alsayed, Javed Iqbal Wani, Muffarah Hamid Alharthi, Abdullah Alshahrani · 2021 · Journal of Personalized Medicine
  92. Investigation of pituitary functions after acute coronavirus disease 2019
    Emre Urhan, Züleyha Karaca, Gamze Kalın Ünüvar, Kürşat Gündoğan, Kürşad Ünlühızarcı · 2022 · Endocrine Journal
  93. Risk of Cardiovascular Events After COVID-19
    Larisa G. Tereshchenko, Adam Bishop, Nora Fisher-Campbell, Jacqueline Levene, Craig C. Morris, Hetal Patel, Erynn A. Beeson, Jessica A. Blank, JG N. Bradner, Michelle Coblens et al. · 2022 · The American Journal of Cardiology
  94. Transferrin receptor is another receptor for SARS-CoV-2 entry
    Xiaopeng Tang, Mengli Yang, Zilei Duan, Zhiyi Liao, Lei Liu, Ruomei Cheng, Mingqian Fang, Wang Gan, Hongqi Liu, Jingwen Xu et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
  95. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis
    Jiuyang Xu, Chaolin Huang, Guohui Fan, Zhibo Liu, Lianhan Shang, Fei Zhou, Yeming Wang, Jiapei Yu, Luning Yang, Ke Xie et al. · 2020 · Frontiers of Medicine
  96. COVID-19 and Microvascular Disease: Pathophysiology of SARS-CoV-2 Infection With Focus on the Renin-Angiotensin System
    Daniel Arthur Barata Kasal, Andrea De Lorenzo, Eduardo Vera Tibiriçá · 2020 · Heart Lung and Circulation
  97. Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection
    Z. Khoshkam, Y. Aftabi, P. Stenvinkel, B. P. Lawrence, M. Rezaei, G. Ichihara, S. Fereidouni · 2021 · Journal of Advanced Research
  98. Review of the COVID-19 Risk in Multiple Sclerosis
    Farhan Chaudhry, Cristina Jageka, Phillip David Levy, Mirela Cerghet, Robert P. Lisak · 2021 · Journal of Cellular Immunology
  99. The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism
    Abdolkarim Mahrooz, Giovanna Muscogiuri, Raffaella Buzzetti, Ernesto Maddaloni · 2021 · Endocrine
  100. COVID-19 and cardiovascular disease: manifestations, pathophysiology, vaccination, and long-term implication
    Adel Abdel‐Moneim, Marwa A. Radwan, Ahmed I. Yousef · 2022 · Current Medical Research and Opinion